Indivior Pharmaceuticals Inc. (INDV) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Indivior Pharmaceuticals Inc. (INDV) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (62/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+340.0% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How INDV Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | 80.2% | 21.1% | $210.0M | -$93.0M | 95% |
| FY 2024 | $1.19B | 80.6% | 3.2% | $7.0M | $7.0M | 95% |
| FY 2023 | $1.09B | 44% | -13.9% | -$126.0M | -$349.2M | -8.7% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring INDV)
- ✓Live walkthrough of INDV's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
INDV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INDV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INDV. Explore sector supply chains on /butterfly.
INDV Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Indivior Pharmaceuticals Inc. (INDV)?
In FY 2025 (10-K), INDV converted $1.2B of revenue into a 80.2% gross margin, 21.1% operating margin, and $0 in free cash flow (0% FCF margin).